Research

Hormonal

Tirzepatide, a dual GIP/GLP-1 receptor agonist, can cause immediate, systemic IgE-mediated hypersensitivity reactions (including urticaria and pruritus) shortly after the initial dose.

If you are prescribed Tirzepatide, be aware that a small percentage of users (1-2%) may experience an allergic reaction, such as hives or itching, shortly after the injection. This can happen even if you tolerated other GLP-1 drugs like semaglutide. If you develop a rash, hives, or difficulty breathing within minutes to hours of your dose, seek medical attention immediately and discontinue the drug.

LimitedSupportsLOW confidence
Around 10-15 minutes after the initial administration of tirzepatide, she experienced a sudden onset of severe disseminated pruritus, accompanied by a generalized urticarial rash... The patient was diagnosed with an immediate-type allergic reaction to tirzepatide, which is believed to be system-wide and potentially mediated by immunoglobulin E (IgE).
Trang Thi Bich Le et al. · Cureus · 2024

Why this rating

Based on a single case report; however, supported by literature reviews citing similar rare events in clinical trials.

Source

A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide

Trang Thi Bich Le et al. · Cureus · 2024

DOI 10.7759/cureus.51460

case_report · n=1Cited 8×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →